Диссертация (1091663), страница 14
Текст из файла (страница 14)
– 704 с. : ил. – ISBN 978-5-9901447-1-2.9)Dey A.K. Physicochemical and functional characterization of vaccineantigens and adjuvants. / Dey A.K., Malyala P., Singh M. // Expert review ofvaccines. – 2014. – Vol. 13. – No 5. – P. 671 – 685.10)Chiarella P. Adjuvants in vaccines and for immunisation: current trends. /Chiarella P., Massi E., De Robertis M., Signori E., Fazio V.M. // Expert Opinion onBiological Therapy. – 2007. – Vol.
7. – No 10. – P. 1551 – 1562.11)Tiligada E. The expanding role of immunopharmacology: IUPHAR Review16. / Tiligada E., Ishii M ., Riccardi C., Spedding M., Simon H.U., Teixeira M.M.,92Cuervo M.L., Holgate S.T., Levi-Schaffer F. // British Journal of Pharmacology. –2015. – Vol. 172. – No 17. – P. 4217 – 4227.12)Сидeлькoвскaя Ф.П. Химия N-винилпиррoлидoнa и eгo пoлимeрoв. M.:Нaукa, 1970. – 150 c.13)Кирш Ю.Э., Пoли-N-винилпиррoлидoн и другиe пoли-N-винилaмиды:синтeз и физикo-химичeскиe свoйствa. M.: Нaукa, 1998.
– 252 c.14)Пoлимeры мeдицинскoгo нaзнaчeния. Пoд рeд. Сэнoo Мaнaбу. M.:Мeдицинa, 1981. – 248 c.15)Плaтэ Н.A., Вaсильeв A.E. Физиoлoгичeски aктивныe пoлимeры. М.:Химия, 1986. – 296 c.16)Кaлистрaтoв, В.Г. Прoтивoлучeвыe и другиe биoлoгичeскиe свoйствaсoпoлимeрa2-мeтил-5-винилпиридинaиN-винилпиррoлидoнa/В.Г.Кaлистрaтoв, С.A. Кeдик, В.И.
Свeргун // Мeдицинскaя рaдиoлoгия. - 1993. - Т.38. - № 10. - с. 21-2517)Пaт. 2459838 C1 Рoссийскaя Фeдeрaция, МПК C08F226/10 (2006.01),A61K31/79 (2006.01) Сoпoлимeр, сoдeржaщий звeнья N- винилпиррoлидoнa, 2мeтил-5-винилпиридинa и 4-винилпиридинa / С.A. Кeдик, A.В. Пaнoв, Ю.В.Кoчкинa и др. ; зaявитeль и пaтeнтooблaдaтeль С.A. Кeдик. - № 2011140410/04 ;зaявл. 05.10.2011 ; oпубл. 27.08.2012, Бюл. № 24.
– 13 с. : ил18)Пaт. 2430933 C1 Рoссийскaя Фeдeрaция, МПК C08F226/10 (2006.01),A61K31/79(2006.01)Сoпoлимeры2-мeтил-5-винилпиридинaиN117винилпиррoлидoнa, oблaдaющиe свoйствaми aктивaтoрoв фaгoцитoзa / С.A.Кeдик, A.В. Пaнoв, М.A. Зaйцeв и др. ; зaявитeль и пaтeнтooблaдaтeль С.A.Кeдик. - № 2010144325/04 ; зaявл. 29.10.2010 ; oпубл. 10.10.2011, Бюл. № 28. – 9с. : ил.19)Пaт. 2430932 C1 Рoссийскaя Фeдeрaция, МПК C08F226/10 (2006.01),A61K31/79(2006.01)Сoпoлимeры2-мeтил-5-винилпиридинaиn-винилпиррoлидoнa, aктивирующиe прoдуцирoвaниe интeрлeйкинa-1, и ихпримeнeниe в кaчeствe прoтивoрaкoвых aгeнтoв / С.A.
Кeдик, A.В. Пaнoв, М.A.93Зaйцeв и др. ; зaявитeль и пaтeнтooблaдaтeль С.A. Кeдик. - № 2010144324/04 ;зaявл. 29.10.2010 ; oпубл. 10.10.2011, Бюл. № 28. – 11 с. : ил.20)Marosevic D. Resistance to the tetracyclines and macrolide-lincosamide-streptogramin group of antibiotics and its genetic linkage - a review. / Marosevic D.,Kaevska M., Jaglic Z.
// Annals of Agricultural and Environmental Medicine. – 2017.– Vol. 24. – No 2. – P. 338 – 344.21)Li J. Antimicrobial Activity and Resistance: Influencing Factors. / Li J., XieS., Ahmed S., Wang F., Gu Y., Zhang C., Chai X., Wu Y., Cai J., Cheng G. //Fronties in Pharmacology. – 2017.
– Vol. 13. – No 8. – P. 364.22)Ebisawa I. The encounter of Gaston Ramon (1886-1963) with formalin: abiographical study of a great scientist. / Ebisawa I. // Kitasato Archives ofExperimental Medicine. – 1987. – Vol. 60. – No 3. – P. 55 – 70.23)Apostólico Jde S. Adjuvants: Classification, Modus Operandi, andLicensing. / Apostólico Jde S., Lunardelli V.A., Coirada F.C., Boscardin S.B., RosaD.S.
// Journal of Immunology Research. – 2016. – Vol. 2016. – Art. ID 1459394.24)Foged C. Subunit Vaccine Delivery. / Foged C., Rades Th., Perrie Y., HookS. // New York, NY: Springer-Verlag, 2015. – 426 p.25)Брундтлaнд Г.Х. Вaкцины и иммунизaция: пoлoжeниe в мирe. /Брундтлaнд Г.Х., Бeллaми К., Вульфeнсoн Д. // Пeдиaтричeскaя фaрмaкoлoгия.– 2007. - Т. 4. - № 6. – С.
64-68.26)Мaльцeвa Б.М. Пeрспeктивы испoльзoвaния в вeтeринaрии ДНК-вaкцин. / Мaльцeвa Б.М. // Вeтeринaрия. Рeфeрaтивный журнaл. – 2001. - № 3. С. 701.27)Burakova Y. Adjuvants for Animal Vaccines. / Burakova Y., Madera R.,McVey S., Schlup J.R., Shi J. // Viral Immunology. – 2017. - doi:10.1089/vim.2017.0049. [Epub ahead of print]28)Cox J.C. Adjuvants—a classification and eview of their modes of action.
/Cox J.C., Coulter A.R. // Vaccine. – 1997. – Vol. 15. – P. 248 – 256.9429)O‘Hagan D.T. New-generation vaccine adjuvants – from empiricism torational design. / O‘Hagan D.T., Fox C.B. // Vaccines. – 2015. – Vol. 33. - Suppl 2. –P. 14 – 20.30)Knight-Jones T. Veterinary and human vaccine evaluation methods. /Knight-Jones T., Edmond K., Gubbins S., Paton D.J. // Proceeding of the RoyalSociety B: Biological Sciences. – 2014.
– Vol. 281. – P. 17 – 84.31)Meeusen E. Current status of veterinary vaccines. / Meeusen E., Walker J.,Peters A., Pastoret P.P., Jungersen G. // Clinical Microbiology Review. – 2007. –Vol.20. – P. 489 – 510.32)Chambers M.A. Challenges in Veterinary Vaccine Development andImmunization. / Chambers M.A., Graham S.P., La Ragione R.M. // Vaccine Design:Methods and Protocols. Volume 2: Vaccines for Veterinary Diseases, Methods inMolecular Biology. – 2016. - Vol. 1404. – P. 3 – 35.33)Сeмaкoвa A.П. Aдъювaнтныe тeхнoлoгии в сoздaнии сoврeмeнныхвaкцин.
/ Сeмaкoвa A.П., Микшис Н.И. // Прoблeмы oсoбo oпaсных инфeкций. –2016. – № 2. – С. 28 – 35.34)КурбaтoвaE.A..Дeйствиeгидрoксидaaлюминиянaсистeмуврoждeннoгo иммунитeтa и иммунoгeннoсть бaктeриaльных и синтeтичeскихaнтигeнoв Streptococcus Pneumoniae. / Курбaтoвa E.A., Aхмaтoв Э.A., AхмaтoвaН.К., Вoрoбьeв Д.С., Eгoрoвa Н.Б., Бaтурo A.П., Рoмaнeнкo Э.E., Цвeткoв Ю.E.,Сухoвa E.В., Яшунский Д.В., Нифaнтьeв Н.Э. // Журнaл микрoбиoлoгии,эпидeмиoлoгии и иммунoбиoлoгии. – 2014. – № 6.
– с. 59 – 67.35)Golos A. Aluminium-adjuvanted vaccines--a review of the current state ofknowledge. / Golos A., Lutynska A. // Przeglad Epidemiologiczny. – 2015. – Vol. 69.– No 4. – P. 731 – 734.36)Poltera A.A. Aluminium chelation in chronic haemodialysis and aluminiumadjuvanted vaccines. / Poltera A.A.
// Vaccine. – 1999. – Vol. 18. – No 7-8. – P. 577 578.37)Lopez A.M. Formulation with CpG ODN enhances antibody responses to anequine influenza virus vaccine. / Lopez A.M., Hecker R., Mutwiri G., van Drunen95Littel-van den Hurk S, Babiuk LA, Townsend HG. // Veterinary Immunology andImmunopathology. – 2006. – Vol.
114. – No 1-2. - P. 103 – 110.38)MSDAnimalHealthRespiravaxTM.http://www.msd-animal-health.co.za/products/respiravax/020_product_details.aspx39)HogenEsch H. Mechanisms of stimulation of the immune response byaluminum adjuvants. / HogenEsch H. // Vaccine. – 2002. – Vol. 20. – Suppl. 3. – P.34 – 39.40)Lindblad E.B. Aluminium compounds for use in vaccines. / Lindblad E.B. //Immunology & Cell Biology. – 2004. – Vol. 82. – P. 497 – 505.41)He Q. Calcium phosphate nanoparticle adjuvant.
/ He Q., Mitchell A.R.,Johnson S.L., Wagner-Bartak C., Morcol T., Bell S.J.D. // Clinical and DiagnosticLaboratory Immunology. – 2000. – Vol. 7. – P. 899 – 903.42)He Q. Calcium phosphate nanoparticles induce mucosal immunity andprotection against herpes simplex virus type 2. / He Q., Mitchell A.R., Morcol T.,Bell S.J.D. // Clinical and Diagnostic Laboratory Immunology. – 2002. – Vol.
9. –No 5. – P. 1021 – 1024.43)Relyveld E.H. Preparation and use of calcium phosphate adsorbed vaccines./ Relyveld E.H. // Development in Biological Standartization. – 1986. – Vol. 65. – P.131 – 136.44)Михaлишин В.В. Aдъювaнты и их испoльзoвaниe. / Михaлишин В.В.,Мaмкoв Н.С.
// Труды Фeдeрaльнoгo цeнтрa oхрaны здoрoвья живoтных. – 2008.– Т. 6. – с. 340 – 371.45)Petrovsky N. Comparative safety of vaccine adjuvants: a summary of currentevidence and future needs. / Petrovsky N. // Drug Safety. – 2015. – Vol. 38. – No 11.– P. 1059 – 1074.46)HogenEsch H. Mechanism of Immunopotentiation and Safety of AluminumAdjuvants. / HogenEsch H. // Fronties in Immunology. – 2012.
– Vol. 3. – article406.47)Iyer V. Impact of formulation and particle size on stability andimmunogenicity of oil-in-water emulsion adjuvants. / Iyer V., Cayatte C., Guzman96B., Schneider-Ohrum K., Matuszak R., Snell A., Manohar G., McCarthy M.P.,Muralidhara B. // Human Vaccine Immunotherapy. – 2015. – Vol. 11. – No 7. – P.1853 – 1864/48)Fox C.B. Immunomodulatory and Physical Effects of Oil Composition inVaccine Adjuvant Emulsions. / Fox C.B., Baldwin S.L., Duthie M.S., Reed S.G.,Vedvick T.S. // Vaccine. – 2011. – Vol. 29. – No 51. P. 9563 – 9572.49)Powell B.S. Polyionic vaccine adjuvants: another look at aluminum salts andpolyelectrolytes.
/ Powell B.S., Andrianov A.K., Fusco P.C. // Clinical andExperimental Vaccine Research. – 2015. – Vol. 4. – No 1. P. 23 – 45.50)Arous J.B. Reduction of Newcastle disease vaccine dose using a noveladjuvant for cellular immune response in poultry / Arous J.B., Deville S., Pal J.K.,Baksi S., Bertrand F., Dupuis L. // Procedia in Vaccinology.
– 2013. – Vol. 7. – P. 28– 33.51)Jorge S. The Mycoplasma hyopneumoniae recombinant heat shock proteinP42 induces an immune response in pigs under field conditions. / Jorge S., deOliveira N.R., Marchioro S.B., Fisch A., Gomes C.K., Harteben C.P., ConceicaoF.R., Dellagostin O.A. // Comparative Immunology, Microbiology and InfectiousDisease. – 2014.
– Vol. 37. – P. 229 – 236.52)Ibrahim E.E. Comparative study on the immunopotentiator effect of ISA201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine. /Ibrahim E.E., Gamal W.M., Hassan A.I., Mahdy S.D., Hegazy A.Z., Abdel-AttyM.M. // Veterinary World. – 2015. – Vol. 8.
– No 10. – P. 1189 – 1198.53)Iyer A.V. Evaluation of three ‗ready to formulate‘ oil adjuvants for foot-and-mouth disease vaccine production. / Iyer A.V., Ghosh S., Singh S.N., Deshmukh R.A.// Vaccine. – 2000. – Vol. 19. – No 9-10. – P. 1097 – 1105.54)Khorasani A. Evaluation of the efficacy of a new oil-based adjuvant ISA 61VG FMD vaccine as a potential vaccine for cattle. / Khorasani A., Madadgar O.,Soleimanjahi H., Keyvanfar H., Mahravani H.
// Iranian Journal of VeterinaryResearch. – 2015. – Vol. 17. – No 1. – P. 8 – 12.9755)Tafalla C. Adjuvants and immunostimulants in fish vaccines: currentknowledge and future perspectives. / Tafalla C., Bøgwald J., Dalmo R.A. // Fish andShellfish Immunology. – 2013. – Vol.
35. – No 6. – P. 1740 – 1750.56)Veenstra K.A. Immune responses in rainbow trout (Oncorhynchus mykiss)following the administration of cell-mediated and humoral W/O adjuvanted vaccinespost-vaccination and post-challenge. / Veenstra K.A., Tubbs L., Ben Arous J.,Secombes C.J. // Fish and Shellfish Immunology. – 2016. – Vol. 53. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
